Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
News May 06, 2014
Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).
Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms were not disclosed.
RELATED ARTICLES
Researchers Develop New Method to Generate Human Antibodies
NewsResearchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.
READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New Research
NewsAfter performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.
READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast Milk
NewsThe antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360ยบ Approach
Apr 23 - Apr 30, 2018
Login
You must be logged in to post a comment.